According to a recently published report by Research Nester on “Cell Line Development Services Market: Global Demand Analysis & Opportunity Outlook 2019-2027” delivers detailed overview of the global cell line development market in terms of market segmentation by product (reagents & media, equipment; by source (mammalian, non-mammalian); by type (recombinant cell lines, hybridomas, continuous cell lines, primary cell lines); by application (bioproduction, drug discovery, toxicity testing, tissue engineering) and by regions.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
The cell line development services market is segmented by product (reagents & media, equipment; by source (mammalian, non-mammalian); by type (recombinant cell lines, hybridomas, continuous cell lines, primary cell lines); by application (bioproduction, drug discovery, toxicity testing, tissue engineering) and by regions.
Cell line is one of the key tools utilized in research for studying the physiology and biochemistry of cells, the effects of drugs and toxic compounds on the cells, drug screening and development and production of biological compounds. Primary cells are the ones that are cultured directly from a subject and have a limited lifecycle. A preserved cell line can multiply for an indefinite period either through random mutation or else by deliberate modification which are useful especially for creation of therapeutics. The application of cell lines lies in research, bioproduction and diagnostics. Among research, cell lines are used for studying disease, screening, cell-based assays are used during discovery phase and preclinical development. Cell lines are consumed to manufacture a wide range of biotherapeutics comprising of vaccine, recombinant proteins that includes peptides, cytokines, hormones and clotting factors, enzymes and monoclonal antibodies.
Cell line development service market is anticipated to mark a CAGR of 17% during the forecast period i.e. 2019-2027. North America accounted for the largest revenue share owing to higher incidences of infectious diseases and lifestyle disorders, coupled with old age population. Adoption of superior technologies for generating robust and highly productive cell lines for large scale therapeutic production, further accelerating the market growth. Asia Pacific reflected the greatest potential, with rapidly developing economies such as India and China leading the market. Additionally, rising disease burden including cancer, adoption of advanced cell line development techniques in biopharmaceutical industries, escalating demand for patients for advanced biological drugs owing to growing healthcare affordability is fostering the regional growth.
Technological advancement in cell line development market
One of the major influencer for this market is growing technological advancements in cell line development market. Development of scientifically advanced products in biotechnology coupled with huge investments in research and development activities is anticipated to drive the cell line development industry growth. Bioproduction is the largest segment in the industry whereas drug discovery and tissue engineering are among the fastest growing application segments. Rising demand for vaccines and monoclonal antibodies offers promising growth opportunities in near future.
However, complexities in development of stable cell lines and high risk of contamination owing to complex purification methods are restraining the market growth. Furthermore, lack of clear regulatory guidelines and high cost and technical requirement to adhere with accreditations are posing threat to the industry.
This report also provides the existing competitive scenario of some of the key players of the global cell line development services market which includes company profiling of Lonza Group AG, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Merck KGaA, Selexis S.A., Rentschler Biopharma SE, Horizon Discovery Group Plc., WuXi AppTec Group, Boehringer Ingelheim International GmbH, MabPlex Inc., and Catalent, Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global cell line development services market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.